Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey
The temporal decline in HCV Ab prevalence appears related to reduced sensitivity of DBS HCV Ab detection with viral clearance following treatment. Since 2016, HCV treatment uptake has increased markedly including among people who inject drugs. In this context, continuing to monitor HCV Ab prevalence by DBS testing is problematic, with a shift to surveillance of active infection the most relevant to guide policy and practice in this setting.
Authors
- Mitchell Starr (ORCID: https://orcid.org/0000-0001-9521-7496)
- Heidi E. Drummer (ORCID: https://orcid.org/0000-0002-0042-6277)
- Robert Kemp
- Margaret Elena Hellard (ORCID: https://orcid.org/0000-0002-5055-3266)
- Handan Wand (ORCID: https://orcid.org/0000-0002-8279-7652)
- Gregory J. Dore (ORCID: https://orcid.org/0000-0002-4741-2622)
- Sue Heard
- John Kaldor (ORCID: https://orcid.org/0000-0002-7639-4355)
- Philip Cunningham (ORCID: https://orcid.org/0000-0003-2613-6910)
- Lisa Maher (ORCID: https://orcid.org/0000-0001-6020-6519)
- Farzaneh Zolala
Institutions
- Queensland Health (AU)
- Burnet Institute (AU)
- Australian Human Rights Commission (AU)
- St Vincent's Hospital Melbourne (AU)
- St Vincent’s Private Hospital Sydney (AU)
- The George Institute for Global Health (AU)
- Northern Sydney Local Health District (AU)
- St Vincent's Clinic (AU)
- Data61 (AU)
- St Vincents Institute of Medical Research (AU)
Publication Details
- Journal
- International Journal of Drug Policy
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.drugpo.2024.104576
- Citations
- 1
- Primary Topic
- HIV, Drug Use, Sexual Risk
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Gilead Sciences
- Department of Health and Aged Care, Australian Government
- National Health and Medical Research Council